BELLUS Health Inc. (BLU): Price and Financial Metrics


BELLUS Health Inc. (BLU): $10.83

0.30 (+2.85%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BLU to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BLU POWR Grades

  • BLU scores best on the Growth dimension, with a Growth rank ahead of 63.24% of US stocks.
  • BLU's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • BLU's current lowest rank is in the Quality metric (where it is better than 14.39% of US stocks).

BLU Stock Summary

  • BELLUS HEALTH INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 6.73% of US listed stocks.
  • The ratio of debt to operating expenses for BELLUS HEALTH INC is higher than it is for about only 5.55% of US stocks.
  • With a price/sales ratio of 118,111.9, BELLUS HEALTH INC has a higher such ratio than 99.98% of stocks in our set.
  • Stocks that are quantitatively similar to BLU, based on their financial statements, market capitalization, and price volatility, are IDYA, BPMC, RAPT, CLLS, and QURE.
  • BLU's SEC filings can be seen here. And to visit BELLUS HEALTH INC's official web site, go to www.bellushealth.com.

BLU Price Target

For more insight on analysts targets of BLU, see our BLU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.20 Average Broker Recommendation 1.43 (Moderate Buy)

BLU Stock Price Chart Interactive Chart >

Price chart for BLU

BLU Price/Volume Stats

Current price $10.83 52-week high $12.69
Prev. close $10.53 52-week low $4.98
Day low $10.75 Volume 221,802
Day high $10.95 Avg. volume 943,036
50-day MA $10.95 Dividend yield N/A
200-day MA $8.44 Market Cap 1.36B

BELLUS Health Inc. (BLU) Company Bio


BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.


BLU Latest News Stream


Event/Time News Detail
Loading, please wait...

BLU Latest Social Stream


Loading social stream, please wait...

View Full BLU Social Stream

Latest BLU News From Around the Web

Below are the latest news stories about BELLUS HEALTH INC that investors may wish to consider to help them evaluate BLU as an investment opportunity.

Bellus: Expected Phase 3 Start Makes This A Long-Term Play

BELLUS Health Inc. (BLU) is a great long-term biotech play to look into. The reason why I state that is because it intends to initiate two phase 3 studies in Q4 of 2022 known as CALM-1 and CALM-2.

It will be using its drug BLU-5937 for the treatment of patients with refractory chronic cough ((RCC)). The reason why it is able to advance this program is because of a positive end-of-phase 2 meeting with the FDA. Investors may have to wait a bit to see the final results of the phase 3 studies, because final results won't be released until the 2nd half of 2024. However, the company just raised additional cash in July 2022, and it believes i...

Terry Chrisomalis on Seeking Alpha | September 7, 2022

BELLUS Health to Present at the H.C. Wainwright Global Investment Conference

LAVAL, Quebec, September 06, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the H.C. Wainwright Global Investment Conference.

Yahoo | September 6, 2022

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index

As a result of the quarterly review, S&P Dow Jones Indices will make the following changes in the S&P/TSX Composite Index and S&P/TSX 60 Index prior to the open of trading on Monday, September 19, 2022:

Yahoo | September 2, 2022

BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022

LAVAL, Quebec, August 22, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that three abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming European Respiratory Society ("ERS") International Congress 2022, being held in Barcelona, S

Yahoo | August 22, 2022

2 Monster Growth Stocks That Could Reach New Highs

Every investor knows that you can’t look to a stock’s past performance as predictor of future gains. It’s become axiom, even, one of the stock phrases that we all learn about in Econ 101: ‘Past performance does not guarantee future returns’ is common formulation. But that simple phrase, while true, raises a tough question: How should an investor judge a stock? The truth is, past is prologue, not prophet, and investors can profit by taking past performance as one of many factors in evaluating a stock.

Michael Marcus on TipRanks | August 14, 2022

Read More 'BLU' Stories Here

BLU Price Returns

1-mo -7.20%
3-mo -0.37%
6-mo 34.20%
1-year 79.90%
3-year 56.28%
5-year 908.47%
YTD 34.53%
2021 163.07%
2020 -59.74%
2019 175.96%
2018 155.26%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7728 seconds.